female doctor

Medical Device Maker Boston Scientific to Buy Axonics for $3.7 Billion

Medical device maker Boston Scientific (BSX.N), said on Monday it had agreed to buy Axonics Inc (AXNX.O), for $3.7 billion, gaining access to devices used to improve bladder function.  The deal marks Boston Scientific’s entry into sacral neuromodulation, a minimally invasive procedure used in the treatment of overactive bladder and fecal incontinence, and is the latest in efforts to scale up its urology business. Read more.
Source: Reuters, January 8, 2024
pelvic vaginal mesh stress urinary incontinence Polypropylene vaginal mesh

FDA Halts All Sales of Pelvic Mesh Products Tied to Injuries in Women

The U.S. Food and Drug Administration on Tuesday announced a ban on the sale of all pelvic mesh products.  The surgical mesh is typically used to repair pelvic organ prolapse (POP) and incontinence, but reported side effects have included permanent incontinence, severe discomfort and an inability to have sex.  “In order for these mesh devices to stay on the market, we determined that we needed evidence that they worked better than surgery without the use of mesh to repair POP,” said Dr. Jeffrey Shuren, director of the FDA’s Center for Devices and Radiological Health. “That evidence was lacking in these premarket applications, and we couldn’t assure women that these devices were safe and effective long term.” Read more.

Source: HealthDay News, April 16, 2019

pelvic vaginal mesh stress urinary incontinence Polypropylene vaginal mesh

Boston Scientific Touts 3-year Solyx Stress Urinary Incontinence Mesh Trial Data

Boston Scientific (NYSE:BSX) this week released three-year data from a study of its Solyx single incision sling system intended to treat stress urinary incontinence, touting that the trial met all primary and secondary endpoints. Boston Scientific said it presented the full results from the trial yesterday at the annual scientific symposium of the American Urogynecologic Society. The Marlborough, Mass.-based company said it enrolled a total 281 patients in the trial at 21 sites looking to compare efficacy and adverse events for non-inferiority of the Solyx system versus the gold-standard transobturator mid-urethral sling procedure. The study was part of a post-market surveillance trial required by the FDA to be performed by all manufacturers of mesh products, Boston Scientific said. The company touted it as the first of three such studies it will complete, with remaining data expected to be released next year. Read more.

Source: Mass Device, October 12, 2018